
ARA-290
ARA-290 (Cibinetide)
ARA-290, also known as cibinetide, is an 11-amino-acid peptide designed from the three-dimensional structure of erythropoietin (EPO). Researchers found that EPO's tissue-protective effects are separate from its red blood cell–stimulating effects, and that they involve a different receptor. ARA-290 mimics a specific surface of EPO (helix B) that engages this tissue-protective receptor without activating the classic EPO receptor that drives red blood cell production.
That separation makes ARA-290 a tool for studying tissue protection and inflammation without the hematological effects of EPO itself. It has been investigated in cell and animal models of nerve injury, inflammation, ischemic stroke and metabolic stress.
ARA-290 is an investigational compound and is not approved by the FDA. PhysIQ Peptides supplies it as a lyophilized powder, third-party tested for purity and identity, for in vitro and laboratory research use only.
Choose how to buy
You save $2.25 every reship · ≈ $27.38 saved per year
Auto-delivered • Skip or cancel anytime • Never run out
Your first order ships at the regular price. Every reship after that is 5% off. Pause, change the interval, or cancel anytime.
- Purity
- ≥99%
- Form
- Powder (lyophilized)
- CAS Number
- 1208243-50-8
- Molecular Formula
- C51H84N16O21
- Molecular Weight
- 1257.31 g/mol
- Available sizes
- 10mg
Sequence
pGlu-Glu-Gln-Leu-Glu-Arg-Ala-Leu-Asn-Ser-Ser
Mechanism of Action
ARA-290 activates the innate repair receptor (IRR), a heteromer of the EPO receptor and the β-common receptor (CD131), which is upregulated in injured or stressed tissue. Signaling through this receptor is reported to reduce pro-inflammatory cytokine production and apoptosis in research models, without stimulating erythropoiesis.
Research Areas
- ●Innate repair receptor (EPOR / CD131) signaling
- ●Nerve injury models
- ●Ischemia and tissue-protection research
- ●Inflammation and cytokine signaling
Selected References
- Wang RL, et al. CNS Neurosci Ther. 2024;30(3):e14676.




